Meta-inflammation in Hidradenitis suppurativa: from pathogenic evidence to therapeutic approaches - Takeaways - MDSpire

Meta-inflammation in Hidradenitis suppurativa: from pathogenic evidence to therapeutic approaches

  • By

  • Chiara Moltrasio

  • Abbas Khan

  • Namra Ahmad

  • Muhammad Adil Malik

  • Paola Maura Tricarico

  • Sergio Crovella

  • Abdelali Agouni

  • Angelo Valerio Marzano

  • May 25, 2026

  • 0 min

Share

  • 1

    Hidradenitis suppurativa (HS) is a chronic inflammatory skin disorder linked to systemic inflammation and metabolic dysfunction.

  • 2

    Meta-inflammation connects HS with metabolic syndrome, driven by pro-inflammatory cytokines like TNF-α, IL-1β, and IL-6.

  • 3

    HS significantly impacts patients' quality of life, often leading to insomnia, anxiety, depression, and suicidal thoughts.

  • 4

    The pathogenesis of HS involves a complex interplay of immune responses, genetic predisposition, and environmental factors.

  • 5

    Novel immunometabolic therapies targeting meta-inflammation may enhance treatment outcomes for HS and its comorbidities.

Original Source(s)

Meta-inflammation in Hidradenitis suppurativa: from pathogenic evidence to therapeutic approaches

  • by Chiara Moltrasio, Abbas Khan, Namra Ahmad, Muhammad Adil Malik, Paola Maura Tricarico, Sergio Crovella, Abdelali Agouni, Angelo Valerio Marzano

  • May 25, 2026

Related Content

Efficacy and Safety of Tildrakizumab for Treatment of Moderate-to-Severe Scalp Psoriasis in Patients with Obesity Over 52 Weeks

Cancer Risk Assessment in Individuals with Hidradenitis Suppurativa: A Comprehensive Review and Meta-Analysis

Combo Therapy for Psoriasis With Obesity

A phase 3b trial tests ixekizumab plus tirzepatide in adults with moderate-to-severe plaque psoriasis and obesity or overweight.